NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $52.31 -0.63 (-1.20%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Lantheus Stock (NASDAQ:LNTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lantheus alerts:Sign Up Key Stats Today's Range$52.29▼$52.9350-Day Range$51.87▼$83.8352-Week Range$47.25▼$118.21Volume337,643 shsAverage Volume1.20 million shsMarket Capitalization$3.56 billionP/E Ratio13.89Dividend YieldN/APrice Target$89.67Consensus RatingModerate Buy Company Overview Lantheus Holdings, Inc. is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications. The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow. On the molecular imaging side, Lantheus markets Cardiolite® (technetium Tc-99m sestamibi) for myocardial perfusion imaging and Lexiscan® (regadenoson) for pharmacologic stress testing. In 2021, the company gained FDA approval and launched PYLARIFY® (piflufolastat F 18), a PET imaging agent for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Lantheus also maintains a robust pipeline of next-generation PET and therapeutic candidates in collaboration with academic and industry partners. Founded in 1956, Lantheus has expanded its reach through strategic acquisitions and global partnerships, serving hospitals, imaging centers and research institutions in more than 50 countries. The company operates a network of manufacturing facilities across North America and Europe, adhering to stringent quality and regulatory standards. Lantheus’ leadership team comprises experienced executives from the pharmaceutical and medical imaging industries, guiding the organization’s growth in precision diagnostics and targeted radiopharmaceutical therapies. Continuous investment in research and development underpins Lantheus’ mission to deliver innovative solutions that improve patient outcomes and drive value for healthcare providers worldwide.AI Generated. May Contain Errors. Read More Lantheus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreLNTH MarketRank™: Lantheus scored higher than 91% of companies evaluated by MarketBeat, and ranked 103rd out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialLantheus has a consensus price target of $91.60, representing about 74.3% upside from its current price of $52.56.Amount of Analyst CoverageLantheus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lantheus' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.99% Earnings GrowthEarnings for Lantheus are expected to grow by 4.99% in the coming year, from $6.01 to $6.31 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 14.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.25.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 14.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.52.Price to Book Value per Share RatioLantheus has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.33% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Lantheus has recently increased by 12.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.67 Percentage of Shares Shorted11.33% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Lantheus has recently increased by 12.22%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.42 News SentimentLantheus has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 49 news articles for Lantheus this week, compared to 13 articles on an average week.Search Interest23 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 21% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $382,427,380.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNTH Stock News HeadlinesInsider Selling: Lantheus (NASDAQ:LNTH) Insider Sells 41,000 Shares of StockAugust 22, 2025 | insidertrades.comLaw Offices of Frank R. Cruz Encourages Lantheus Holdings, Inc. (LNTH) Investors To Inquire About Securities Fraud Class Action1 hour ago | businesswire.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.September 15 at 2:00 AM | Priority Gold (Ad)Class Action Announcement LNTH: A Securities Fraud Class Action Lawsuit Was Filed Against Lantheus Holdings, Inc. (LNTH)2 hours ago | theglobeandmail.comJohnson Fistel Announces Class Action Lawsuit Against Lantheus Holdings, Inc. (LNTH) on Behalf of Investors3 hours ago | globenewswire.comThe Gross Law Firm Reminds Lantheus Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 10, 2025 - LNTH4 hours ago | prnewswire.comLNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 15 at 3:11 AM | prnewswire.comLNTH INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lantheus Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 14 at 12:00 PM | prnewswire.comSee More Headlines LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $89.46 on January 1st, 2025. Since then, LNTH stock has decreased by 41.2% and is now trading at $52.56. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings results on Wednesday, August, 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by $0.08. The business's revenue was down 4.1% compared to the same quarter last year. Read the conference call transcript. When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Top institutional investors of Lantheus include Geode Capital Management LLC (2.57%), Westfield Capital Management Co. LP (2.20%), Reinhart Partners LLC. (2.03%) and TD Asset Management Inc (0.91%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Farallon Partners L L C/Ca, Rajiv A Patel, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, James H Thrall, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden and Minnie Baylor-Henry. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings8/06/2025Today9/15/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees700Year FoundedN/APrice Target and Rating Average Price Target for Lantheus$91.60 High Price Target$143.00 Low Price Target$63.00 Potential Upside/Downside+73.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$3.76 Trailing P/E Ratio14.08 Forward P/E Ratio8.81 P/E GrowthN/ANet Income$312.44 million Net Margins17.82% Pretax Margin24.75% Return on Equity34.06% Return on Assets19.10% Debt Debt-to-Equity Ratio0.49 Current Ratio4.29 Quick Ratio4.07 Sales & Book Value Annual Sales$1.53 billion Price / Sales2.35 Cash Flow$7.10 per share Price / Cash Flow7.46 Book Value$15.65 per share Price / Book3.38Miscellaneous Outstanding Shares67,990,000Free Float66,634,000Market Cap$3.60 billion OptionableOptionable Beta0.15 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:LNTH) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LNTH Stock Alerts